Further studies are necessary to evaluate the role of FGF-23 and the RANK/RANKL/OPG system in renal osteodystrophy and define if new medications, used to improve bone quality in non-dialysis patients, could influence bone turnover and mineralization in HD patients. Here, TNFRSF11A is linked to renal osteodystrophy.